Linguistic Validation & COATranslation Services

Linguistic validation is a rigorous, multi-step process for translating and culturally adapting Patient Reported Outcome (PRO) instruments to ensure that the translated version measures the same construct as the original and is understood in the same way by target language patients. FDA's 2009 PRO Guidance and EMA's Reflection Paper require linguistic validation for PRO instruments used as primary or key secondary endpoints in clinical trials supporting regulatory submissions.

We follow the ISPOR Task Force recommendations for translation and cultural adaptation of patient-reported outcome measures — the industry gold standard for LV methodology. Our standard process includes forward translation by two independent translators, reconciliation, back-translation, expert committee review, cognitive debriefing interviews with target language patients, and final review. Each step is documented in a comprehensive LV dossier.

Yes. We provide linguistic validation of electronic Clinical Outcome Assessment (eCOA) and electronic Patient Reported Outcome (ePRO) platforms, including screen-by-screen review of translated interfaces, user interface testing with target language patients, and validation of all system-generated messages. We are familiar with the major eCOA platforms used in clinical trials, including Medidata Rave, Veeva Vault, and Oracle Clinical One.

We cover 80+ languages for linguistic validation, with particular depth in the major clinical trial languages: English, Spanish, French, German, Italian, Portuguese, Japanese, Chinese (Simplified and Traditional), Korean, Russian, and Dutch. For rare languages, we can typically mobilize qualified LV teams within 72 hours.

A standard full linguistic validation project (forward translation, reconciliation, back-translation, expert committee review, cognitive debriefing, final version) typically takes 8–12 weeks per language. Expedited timelines are available for urgent programs. For instruments that have been previously validated in a language, we can provide a review and update process that is significantly faster.

Yes. We prepare comprehensive linguistic validation dossiers that meet FDA PRO Guidance and EMA Reflection Paper requirements. The dossier includes all translation documentation, back-translation reports, expert committee meeting minutes, cognitive debriefing interview transcripts and analysis, and a final validation report. The dossier is formatted for inclusion in regulatory submissions.

Yes. We have validated numerous quality of life instruments including SF-36, EQ-5D-3L and EQ-5D-5L, FACT-G and disease-specific FACT modules, EORTC QLQ-C30 and modules, and many other HRQoL measures. For instruments with existing validated translations, we can provide a review and update process rather than a full de novo validation.

Cognitive debriefing interviews are conducted with 5–10 target language patients who represent the target population for the clinical trial. Interviews are conducted by trained qualitative researchers in the target language, using a standardized debriefing guide. Patients are asked to read each item aloud, explain what they understand it to mean, and indicate whether the item is relevant to their experience. Interview transcripts are analyzed to identify comprehension issues and inform final revisions.